Genomics of Drug Sensitivity

The Genomics of Drug Sensitivity (GDS)

Anti-cancer drugs are screened against a large collection (>1000) cancer cell lines representative of many different malignancies to discover links between genotypes and drug response.


Genomics of Drug Sensitivity (GDS)

The Genomics of Drug Sensitivity (GDS) Project is part of a unique 5-year collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center. The Center for Molecular Therapeutics has pioneered the use of high-throughput platforms for examining the relationship between tumor cell genomics and sensitivity to anti-cancer agents. The Cancer Genome Project has led the way in the systematic analysis of cancer genomes to identify genes critical in the development of human cancers. This collaboration will develop and integrate the expertise at both sites toward the goal of identifying cancer biomarkers that can be used to identify genetically defined subsets of patients most likely to respond to targeted therapies.


GDS Announcements Mailing List

Interested in receiving 'Genomics of Drug Sensitivity' (GDS) news and release information? Sign up here.

Group Members

Mass General Cancer Center

Principal Investigator

Scientific Advisors

Project Leader

Post Doctoral Research Fellow

  • Elena Edelman, PhD

Database Technical Specialist

  • Patricia Greninger

Senior Research Assistant

  • Randy Milano

Research Assistants

  • Angela Tam
  • Jesse Stevenson
  • Steve Lutz
  • Xeni Mitropoulos


Wellcome Trust Sanger Institute

Principal Investigators

  • Michael Stratton
  • Andy Futreal

Project Leader

  • Mathew Garnett

Clinician Scientist

  • Ultan McDermott

Postdoctoral Research Fellow

  • Sonja Heidorn

Computer Biologists

  • Richard Thompson
  • Jorge Soares

Senior Research Assistant

  • Anne McLaren-Douglas

Research Assistants

  • Andrew Barthorpe
  • Tatiana Mironenko
  • Laura Hirst
  • Patrick Brien

Back to Top